APIs, Pharmaceutical Intermediates, Biological Products
Glipizide, Flunarizine Dihydrochloride, Loxoprofen Sodium, 4-(2-Aminoethyl)Benzene Sulfonamide, 2-N-Propyl-4-Methyl-6-(1-Methylbenzimidazol-2-Yl)Benzimidazole, 2-(4-Bromomethyl)Phenylpropionic Acid, 6-Carboxy-4-Methyl-2-Propylbenzimidazole, Methyl 2-Oxocyclopentanecarboxylate
Dijia Pharmaceutical Group Co., Ltd., established in 2013, is a national high-tech enterprise that integrates research, development, production, and sales of APIs, pharmaceutical intermediates, and biological products. The company, a subsidiary of Disha Pharmaceutical Group, is committed to producing high-quality, safe, and low-pollution products. Dijia specializes in cardio cerebrovascular, hypoglycemic, and hypolipidemic pharmaceuticals, along with new marine biological materials. The company's products meet international standards and are exported to markets worldwide, including Japan, South Korea, and India.
